স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 60 mg / 1 tableta - dapoksetin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 60 mg / 1 tableta - dapoksetin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 30 mg / 1 tableta - dapoksetin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 30 mg / 1 tableta - dapoksetin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - ovarijske neoplazme - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca je označen kot monotherapy za vzdrževanje zdravljenje odraslih bolnikov s platino-občutljive relapsed visoko-kakovostni razred epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka, ki so v odziv (popolna ali delna) platinum, ki temelji kemoterapijo.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplazme dojke - endokrini terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - hiperholesterolemija - sredstva za spreminjanje lipidov - lojuxta je navedena kot dodatek k dieti low‑fat in drugimi lipid‑lowering zdravili z ali brez citofereza nizko gostoto lipoproteinov (ldl), pri odraslih bolnikih s homozigotno družinsko hiperholesterolemijo (hofh). genetske potrditev hofh, je treba pridobiti, kadar je to mogoče. druge oblike primarne hyperlipoproteinaemia in sekundarne vzroke hypercholesterolaemia (e. nephrotic sindrom, hipotiroidizem) mora biti izključena.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

basilea pharmaceutica deutschland gmbh - isavukonazol - aspergiloza - cresemba je navedeno pri odraslih za zdravljenje:invazivne aspergillosismucormycosis pri bolnikih, za katere amphotericin b je inappropriateconsideration treba uradna smernice za ustrezno uporabo protiglivično agenti.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

jenson pharmaceutical services limited - dextromethorphan, quinidine - nevrološke manifestacije - druga zdravila na živčnem sistemu - zdravilo nuedexta je indicirano za simptomatsko zdravljenje pseudobulbarnega vpliva (pba) pri odraslih. učinkovitost so raziskali samo pri bolnikih z osnovno amiotrofično lateralno sklerozo ali multiplo sklerozo.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).